Improved Tolerability of De Novo Letermovir Over Valganciclovir for Cytomegalovirus Prophylaxis in Seropositive Liver Transplant Recipients
Clinical Transplantation · 2026-06 · 40 (6)
DOI: 10.1111/ctr.70597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, online erschienen am 15.06.2026. Verfasst von Hanna L Kleiboeker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Liver Transplantation, Antiviral Agents, Valganciclovir. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Cytomegalovirus (CMV) can drive negative outcomes after liver transplant (LT). Though valganciclovir (VGC) remains the guideline‐recommended standard‐of‐care, letermovir (LTV) may be beneficial in LT given reduced bone marrow suppression.
Methods
Adult patients receiving a LT with moderate‐risk CMV serostatus (R+) 6/1/2021‐9/30/2024 were evaluated. Patients were assigned to a cohort based on de novo antiviral prophylaxis regimen: VGC or LTV. The primary objective was tolerability and safety of LTV compared to VGC.
Results
Eighty‐five patients met inclusion criteria: 60 in VGC and 25 in LTV cohorts. Significantly more patients in the LTV cohort completed antiviral prophylaxis (VGC 68.3% vs. LTV 92.0%, p = 0.02), with conversion to an alternative strategy occurring a median of 58 days post‐LT in the VGC cohort. No patients terminated LTV due to intolerance or breakthrough. Patients in the VGC cohort were more likely to experience post‐LT leukopenia (VGC 81.7% vs. LTV 52.0%, p = 0.005) and neutropenia (VGC 50.0% vs. LTV 24.0%, p = 0.03), as well as require GCSF support (VGC 25.0% vs. LTV 4.0%, p = 0.024). Patients in the LTV cohort tolerated significantly higher total daily doses (TDD) of mycophenolate at 3 (VGC 1750 mg vs. LTV 2000 mg, p = 0.005) and 6 (VGC 1000 mg vs. LTV 2000 mg, p = 0.04) months post‐LT. Incidence of CMV viremia and acute rejection through 1‐year post‐LT was not significantly different between cohorts.
Conclusion
De novo LTV for CMV prophylaxis in seropositive LT recipients appears to be safe and efficacious. LTV is more likely to be completed compared to VGC and is associated with less myelosuppressive toxicity, allowing for higher doses of mycophenolate. Future studies are needed to definitively evaluate the impact of LTV on rejection rates and transplant outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.
- Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.
- Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.
Zitieren
APA
Kleiboeker, H. L., Descourouez, J. L., Saddler, C. M., Al-Adra, D., Rice, J. P., & Jorgenson, M. R. (2026). Improved Tolerability of De Novo Letermovir Over Valganciclovir for Cytomegalovirus Prophylaxis in Seropositive Liver Transplant Recipients. Clinical Transplantation, 40(6). https://doi.org/10.1111/ctr.70597
Vancouver
Kleiboeker HL, Descourouez JL, Saddler CM, Al-Adra D, Rice JP, Jorgenson MR. Improved Tolerability of De Novo Letermovir Over Valganciclovir for Cytomegalovirus Prophylaxis in Seropositive Liver Transplant Recipients. Clinical Transplantation. 2026;40(6). doi:10.1111/ctr.70597
BibTeX
@article{Kleiboeker2026,
author = {Kleiboeker, Hanna L and Descourouez, Jillian L and Saddler, Chris M and Al-Adra, David and Rice, John P and Jorgenson, Margaret R},
title = {Improved Tolerability of De Novo Letermovir Over Valganciclovir for Cytomegalovirus Prophylaxis in Seropositive Liver Transplant Recipients},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {6},
doi = {10.1111/ctr.70597}
}
EUVIMED